Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF) will participate in the American Society of Clinical Psychopharmacology Annual Meeting in Miami from May 26–29, 2026. Founder Dr. Joseph Geraci joins a plenary on AI in psychiatry, and the company presents two posters on explainable AI–driven precision psychiatry using its NetraAI platform.
NetraMark (OTCQB: AINMF) reported a second quarter 2026 update, emphasizing commercial, scientific, regulatory and capital markets progress for its NetraAI clinical trial analytics platform.
Key items include a Cdn$3.5M private placement, TSX uplisting, new pharma contracts, growing proposals, and a Cdn$2.96M revenue backlog.
NetraMark (OTCQB: AINMF) appointed Dr. Panteli Theocharous as Fractional Chief Medical Officer on May 4, 2026, to support global deployment of the NetraAI platform. Dr. Theocharous will continue his roles at Worldwide Clinical Trials and will advise on clinical strategy, trial design, patient stratification, and regulatory translation. Outgoing CMO Dr. Larry Alphs will remain as an advisor to ensure continuity.
NetraMark (OTCQB: AINMF; TSX: AIAI) will open trading on the Toronto Stock Exchange on May 5, 2026 at the market open ceremony. Senior management will perform the market open at 9:30 AM ET, and the event will be livestreamed.
NetraMark develops the NetraAI platform for clinical trial optimization and patient stratification, and the market open highlights ongoing investor engagement and recent collaborations in oncology and other therapeutic areas.
NetraMark (OTCQB: AINMF) highlights its NetraAI platform as a purpose-built analytics solution to support psychedelic and CNS clinical trials amid recent U.S. executive action. The company cites peer‑reviewed validation in npj Digital Medicine and Frontiers in Pharmacology, ongoing psychedelic trial programs, and an emphasis on explainable, regulator‑ready subgroup identification.
NetraMark stresses that policy momentum does not lower regulatory evidence standards and positions NetraAI to improve patient stratification, signal detection, and trial design for small, heterogeneous datasets.
NetraMark (OTCQB: AINMF) commented on the U.S. Executive Order of April 18, 2026 to accelerate treatments for serious mental illness, including investigational psychedelic programs. NetraMark urged rigorous, regulatory‑grade trial design and highlighted its NetraAI platform for explainable subgroup analytics to improve signal detection in CNS trials.
NetraMark (OTCQB: AINMF) announced a peer-reviewed article published April 9, 2026, in Frontiers in Pharmacology proposing a testable hypothesis linking psychedelics, calcium/phosphate biology, and possible spin-dependent processes.
The paper, led by NetraMark founders, frames inter-individual treatment variability as structured biological heterogeneity and outlines a translational pathway to biomarker-guided, explainable-AI trial design aligned with NetraAI platform capabilities.
NetraMark (OTCQB: AINMF) announced a strategic research collaboration with Fondazione per la Medicina Personalizzata to analyze the ROME Phase II oncology trial dataset (NCT04591431) using NetraMark's NetraAI platform. The ROME trial randomized 400 patients and reported improved overall response rate and progression-free survival for tailored treatment versus standard of care.
The collaboration will seek Model-Derived Subgroups and evaluate endpoints including PFS, ORR, OS, time to treatment failure, and safety, subject to data availability and joint governance.
NetraMark (OTCQB: AINMF) presented a poster at the AD/PD 2026 conference (March 17-21) showing that its explainable AI, NetraAI, identified two treatment-responsive subgroups in the Phase 3 A4 solanezumab dataset.
Findings include biologically interpretable subgroups with preserved limbic/temporal network integrity and effect sizes up to Cohen’s d 1.52, suggesting AI-enabled precision enrichment may reveal masked therapeutic signals.
NetraMark (OTCQB: AINMF) signed a contract with a leading global biopharmaceutical company to analyze data from a Phase 2 depression clinical trial using its NetraAI platform. The engagement aims to identify patient subpopulations, evaluate treatment response patterns, and inform future study design with AI-driven precision insights.
NetraAI applies a dynamical systems framework to multi-dimensional, small clinical datasets to stratify high-effect-size cohorts and translate findings into clinically meaningful trial enrichment criteria.